OPGx-BEST1

N/A

Report date: 2025/11/17 14:58:24

Base Information

Drug NameOPGx-BEST1
Drug Alias NameIC-200OPGx-BEST1
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionBEST1 gene transference
TargetsBestrophin-1
Therapy Area/IndicationsVitelliform Macular Dystrophy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Florida Research Foundation IncUniversity Of Pennsylvania
China Registration ClassN/A

Develop Information

Active CompaniesOphthotech CorpOpus Genetics Inc
Inactive CompaniesIveric Bio Inc
Active IndicationsVitelliform Macular Dystrophy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A